Akela Pharma Inc., a Saint-Laurent, Quebec-based drug company focused on pain therapeutics, has withdrawn registration for a $36.6 million IPO, citing “unfavorable market conditions.” The company currently trades on the TSX, but had filed for a listing on the Nasdaq. Lazard Capital Markets was serving as lead underwriter. Akela shareholders include Atlas Venture (8.5%), Great Point Partners (8.5%) and Sitra (6.64%). www.labinc.ca
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: subscriptions@peimedia.com.